Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mitomycin

FDA-approved product (for solution, topical), marketed as Jelmyto, Mitomycin, Mitosol and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Mitomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Cancer
  • Glaucoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cytotoxic antibiotics
FDA pharmacologic class
Alkylating Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mitomycin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mitomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

    NCT07804056 · start 2026-09-17

    Registered record
    Registry ID
    NCT07804056
    Conditions
    Urinary Bladder Neoplasms; Non-muscle Invasive Bladder Cancer (NMIBC)
    Interventions
    Alpha1H; Transurethral Resection of Bladder Tumor (TURBT); Intravesical Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-09-17
    Completion
    2029-07
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Bladder Neoplasms; Non-muscle Invasive Bladder Cancer (NMIBC)
    InterventionAlpha1H; Transurethral Resection of Bladder Tumor (TURBT); Intravesical Chemotherapy
    PhasePhase 3
    Registry statusRecruiting

  • Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC

    NCT07663747 · start 2026-09-01

    Registered record
    Registry ID
    NCT07663747
    Conditions
    Urothelial Bladder Cancer
    Interventions
    Enfortumab Vedotin; Pembrolizumab; Radiation; Chemoradiation; Cystectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2032-04-01
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Bladder Cancer
    InterventionEnfortumab Vedotin; Pembrolizumab; Radiation; Chemoradiation +1 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

    NCT07043543 · start 2026-01-15

    Registered record
    Registry ID
    NCT07043543
    Conditions
    Bladder Cancer
    Interventions
    Adaptive radiotherapy; standard radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-01-15
    Completion
    2033-09-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer
    InterventionAdaptive radiotherapy; standard radiotherapy
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

    NCT04107077 · start 2025-09-09

    Registered record
    Registry ID
    NCT04107077
    Conditions
    Gastric Cancer; Peritoneal Carcinomatosis
    Interventions
    Cisplatin; Mitomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-09
    Completion
    2026-12-20
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer; Peritoneal Carcinomatosis
    InterventionCisplatin; Mitomycin
    PhasePhase 2
    Registry statusRecruiting

  • SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients

    NCT07152132 · start 2025-07-20

    Registered record
    Registry ID
    NCT07152132
    Conditions
    Glaucoma, Open Angle
    Interventions
    Trabeculectomy; Slow coagulation trans-scleral cyclophotocoagulation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-07-20
    Completion
    2026-12-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open Angle
    InterventionTrabeculectomy; Slow coagulation trans-scleral cyclophotocoagulation
    PhaseNot applicable
    Registry statusRecruiting

  • uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

    NCT05874921 · start 2023-11-17

    Registered record
    Registry ID
    NCT05874921
    Conditions
    Urothelial Carcinoma; Urothelial Carcinoma Recurrent; Urothelial Carcinoma Ureter; Urothelial Carcinoma Ureter Recurrent; Urothelial Cancer of Renal Pelvis; Urothelial Carcinoma of the Renal Pelvis and Ureter; Carcinoma, Transitional Cell; Transitional Cell Carcinoma of Renal Pelvis
    Interventions
    Jelmyto (mitomycin) for pyelocalyceal solution
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-11-17
    Completion
    2028-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Carcinoma; Urothelial Carcinoma Recurrent; Urothelial Carcinoma Ureter; Urothelial Carcinoma Ureter Recurrent +4 more
    InterventionJelmyto (mitomycin) for pyelocalyceal solution
    PhaseNot recorded
    Registry statusRecruiting

  • Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

    NCT05975151 · start 2023-10-01

    Registered record
    Registry ID
    NCT05975151
    Conditions
    Bladder Cancer
    Interventions
    Pseudomonas aeruginosa
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-10-01
    Completion
    2025-12-01
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer
    InterventionPseudomonas aeruginosa
    PhasePhase 2
    Registry statusUnknown

  • REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

    NCT05902533 · start 2023-08-14

    Registered record
    Registry ID
    NCT05902533
    Conditions
    Anal Cancer
    Interventions
    Radiation (reduced elective nodal dose (30.6 Gy); Capecitabine; Mitomycin c
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2023-08-14
    Completion
    2029-08-14
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal Cancer
    InterventionRadiation (reduced elective nodal dose (30.6 Gy); Capecitabine; Mitomycin c
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Severe Neutropenia After HIPEC Using Mitomycin-C

    NCT05513183 · start 2021-05-20

    Registered record
    Registry ID
    NCT05513183
    Conditions
    Colorectal Cancer Metastatic; Cancer Metastatic to the Peritoneal Cavity; Appendiceal Neoplasm; Pseudomyxoma Peritonei
    Interventions
    Intraoperative blood and peritoneal fluid samplings during HIPEC
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-05-20
    Completion
    2023-03-20
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic; Cancer Metastatic to the Peritoneal Cavity; Appendiceal Neoplasm; Pseudomyxoma Peritonei
    InterventionIntraoperative blood and peritoneal fluid samplings during HIPEC
    PhaseNot recorded
    Registry statusCompleted

  • Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies

    NCT04729205 · start 2021-01-13

    Registered record
    Registry ID
    NCT04729205
    Conditions
    Cancer; Gastro-Intestinal Intraepithelial Neoplasia
    Interventions
    Promitil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-01-13
    Completion
    2023-09-12
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Gastro-Intestinal Intraepithelial Neoplasia
    InterventionPromitil
    PhasePhase 1
    Registry statusTerminated

  • SIGHT Study: Cost-effectiveness of InnFocus Microshunt Implantation vs. Trabeculectomy.

    NCT03931564 · start 2020-02-01

    Registered record
    Registry ID
    NCT03931564
    Conditions
    Primary Open-angle Glaucoma
    Interventions
    PRESERFLO Microshunt implantation; Trabeculectomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-02-01
    Completion
    2024-12-01
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open-angle Glaucoma
    InterventionPRESERFLO Microshunt implantation; Trabeculectomy
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of UGN-101 in Recurrent Patients

    NCT04006691 · start 2019-10-01

    Registered record
    Registry ID
    NCT04006691
    Conditions
    Carcinoma; Transitional Cell Carcinoma; Transitional Cell Cancer of the Renal Pelvis and Ureter
    Interventions
    UGN-101 instillations
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2019-10-01
    Completion
    2020-03-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma; Transitional Cell Carcinoma; Transitional Cell Cancer of the Renal Pelvis and Ureter
    InterventionUGN-101 instillations
    PhasePhase 3
    Registry statusWithdrawn

  • Ab Interno Gelatin Stent With Mitomycin C Using Targeted Supra-tenon's Placement

    NCT04454138 · start 2019-06-25

    Registered record
    Registry ID
    NCT04454138
    Conditions
    Glaucoma
    Interventions
    XEN-45 gelatin microstent
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-06-25
    Completion
    2020-04-20
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionXEN-45 gelatin microstent
    PhaseNot recorded
    Registry statusCompleted

  • Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy

    NCT03875911 · start 2019-03-30

    Registered record
    Registry ID
    NCT03875911
    Conditions
    Glaucoma Open-Angle Primary; Glaucoma; Open Angle Glaucoma; Glaucoma, Open-Angle
    Interventions
    Mitomycin C
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-03-30
    Completion
    2022-12-31
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma Open-Angle Primary; Glaucoma; Open Angle Glaucoma; Glaucoma, Open-Angle
    InterventionMitomycin C
    PhasePhase 4
    Registry statusTerminated

  • A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

    NCT03844256 · start 2019-01-07

    Registered record
    Registry ID
    NCT03844256
    Conditions
    Urinary Bladder Cancer; Invasive Bladder Cancer
    Interventions
    nivolumab 480mg; nivolumab 3mg/kg, ipilimumab 1mg/kg; nivolumab 1mg/kg, ipilimumab 3mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2019-01-07
    Completion
    2026-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Bladder Cancer; Invasive Bladder Cancer
    Interventionnivolumab 480mg; nivolumab 3mg/kg, ipilimumab 1mg/kg; nivolumab 1mg/kg, ipilimumab 3mg/kg
    PhasePhase 1 / Phase 2
    Registry statusUnknown